{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-189765","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2025-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.345428+00:00","generated_at":"2026-05-17T09:42:06.683081+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prothena PRX012 shows amyloid reduction but higher ARIA-E rates; seeks partnership","bullets":["Phase 1 ASCENT: PRX012 400 mg achieved mean amyloid PET reduction to 27.47 CL at month 12.","ARIA-E rates at 400 mg (41.7%) and 200 mg (38.1%) exceeded those of FDA-approved anti-Aβ antibodies.","One death in 45 mg cohort deemed unrelated to study drug; injection site reactions low (4.1%).","Company plans to explore partnership to advance PRX012 and preclinical PRX012-TfR antibody."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-189765","json":"https://secwatch.observer/filing/0001193125-25-189765.json","markdown":"https://secwatch.observer/filing/0001193125-25-189765.md","text":"https://secwatch.observer/filing/0001193125-25-189765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000119312525189765/0001193125-25-189765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000119312525189765/d38911d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:42:06.683081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}